Internal Reference Number: FOI_7667
Date Request Received: 12/01/2024 00:00:00
Date Request Replied To: 31/01/2024 00:00:00
This response was sent via: By Email
Request Summary: biologic medicines in dermatology
Request Category: Researcher
| Question Number 1: I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following two questions: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab | |
| Answer To Question 1: • Adalimumab - Humira - 15 • Adalimumab Biosimilar - <5 • Apremilast - <5 • Bimekizumab - <5 • Brodalumab - 6 • Certolizumab - <5 • Deucravacitinib - 0 • Dimethyl fumarate - 0 • Etanercept - Enbrel - 0 • Etanercept Biosimilar - 0 • Guselkumab - 25 • Infliximab - Remicade - 0 • Infliximab Biosimilar - 0 • Ixekizumab - 6 • Risankizumab - 6 • Secukinumab - <5 • Tildrakizumab - 7 • Ustekinumab - <5 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following: • Ciclosporin • Methotrexate - any form and strength • Methotrexate injections 15mg and above | |
| Answer To Question 2: Ciclosporin- 5 patients Methotrexate- 10 patients none on injections of methotrexate- all oral meds | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
